ScreenerHero

INCY Incyte Corporation - Common Stock

NAS · US · Healthcare · Biotechnology · incyte.com
114.93USD-0.33%Mkt Cap: 23.37B $P/E: 14.69

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment o…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD
BBIO
BridgeBio Pharma, Inc. - Common Stock
$13.15BUSD

Key Statistics

Company
Market Cap23.37B USD
Enterprise Value18.87B USD
Revenue (TTM)5.82B USD
Gross Profit4.77B USD
Net Income (TTM)1.29B USD
Revenue/Share29.36 USD
Last Price114.93 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)14.69
P/E (Forward)13.13
PEG10.82
EV/EBITDA9.72
EV/Revenue3.24
P/S4.02
P/B3.65
EPS (TTM)7.85
EPS (Forward)8.78
52W Range
81.0966% of range132.58
52W High132.58 USD
52W Low81.09 USD
Profitability
Gross Margin92.76%
Oper. Margin41.90%
EBITDA Margin33.38%
Profit Margin25.03%
ROE24.90%
ROA18.49%
Growth
Revenue Growth37.70%
Earnings Growth37.70%
Cash Flow & Leverage
Operating CF1.41B USD
CapEx (TTM)83.87M USD
FCF Margin20.29%
FCF Yield5.05%
Net Debt-4.50B USD
Net Debt/EBITDA-2.32
Balance Sheet
Debt/Equity0.01
Current Ratio4.59
Quick Ratio4.31
Book Value/Sh31.57 USD
Cash/Share22.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateSep 1, 2000
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)128.42 USD
Upside (mean)+11.7%
Target Range86.00 USD – 155.00 USD
86.00+11.7% to mean155.00
# Analysts24
Ownership
Shares Out.202.70M
Float170.73M
Insiders1.85%
Institutions103.43%
Short Interest
Short Ratio7.6d
Short % Float8.39%
Short % Out.4.92%
Shares Short9.98M
Short (prev mo.)9.39M
Technical
SMA 50123.63 (-7.0%)
SMA 200106.86 (+7.6%)
Beta0.77
S&P 52W Chg14.58%
Avg Vol (30d)1.45M
Avg Vol (10d)1.64M
Technical Indicators
RSI (14)33.7
MACD-0.9315
MACD Signal0.2599
MACD Hist.-1.1914
BB Upper130.42 USD
BB Middle123.87 USD
BB Lower117.32 USD
BB Width10.58%
ATR (14)3.446 USD
Vol Ratio (20d)1.38x